US stocks delivered a positive performance on Wednesday, April 23, after President Trump pointed out that he does not intend to fire Federal Reserve Chair Jerome Powell. This statement helped ease Wall Street’s fears about the independence of the central bank. Additionally, Trump softened his tone on tariffs and hinted that the high duties on Chinese imports could be scaled back in the future.
READ ALSO: 14 Best American Tech Stocks To Buy Now and 10 Best Electronic Components Stocks to Buy Now.
The Nasdaq led the gains as it increased by 2.5%. The S&P 500 rose nearly 1.7%, and the Dow Jones Industrial Average increased about 1.1%, or 400 points. Earlier in the day, the Nasdaq was up over 4% at one point and the Dow had added about 1,100 points. However, these gains faded after Treasury Secretary Scott Bessent told reporters there has been “no unilateral offer from the president to deescalate” the trade war with China.
Despite this pullback, Wall Street remained optimistic because of President Trump’s softer tone on both the Fed and tariffs. On Tuesday, Trump said he expects China tariffs to come down significantly after Bessent had called the current tariffs “unsustainable.”
Trump also told reporters from the Oval Office that he never intended to remove Powell but repeated his desire for the Fed chair to lower interest rates. These comments brought relief to investors who had feared that a possible conflict between President Trump and Powell could add further uncertainty in a market that is already affected by tariffs.
With this background in mind, let’s take a look at the 13 best aggressive growth stocks to buy now.
A financial analyst looking at a monitor displaying the stocks of the public company.
Our Methodology
To compile our list of the 13 best aggressive growth stocks to buy now, we looked for stocks with a year-over-year revenue growth rate exceeding 35%. To ensure the reliability of our findings, we consulted SeekingAlpha for the year-over-year revenue growth rate for each company. Next, we focused on the top 13 aggressive growth stocks most favored by institutional investors. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q4 2024 database of more than 1,000 elite hedge funds. Finally, the 13 best aggressive growth stocks to buy now were ranked in ascending order based on the number of hedge funds holding stakes in them as of Q4 2024.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13 Best Aggressive Growth Stocks to Buy Now
13. Coinbase Global, Inc. (NASDAQ:COIN)
Year-Over-Year Revenue Growth: 115.04%
Number of Hedge Fund Holders: 69
Coinbase Global, Inc. (NASDAQ:COIN) is an American technology company that operates a platform for trading, staking, storing, and transferring crypto assets. The company serves people and institutions in more than 100 countries. Coinbase Global, Inc. (NASDAQ:COIN) ranks among the best aggressive growth stocks to buy now.
The company is making strategic moves to grow its business, invest in platform improvements, and expand into new markets and products. In 2024, Coinbase Global, Inc. (NASDAQ:COIN) reported that total revenue more than doubled to reach $6.6 billion, with adjusted EBITDA reaching $3.3 billion for the year. The company’s subscription and services revenue increased 64% year-over-year to $2.3 billion. This growth was driven by USDC, staking, and Coinbase One. In Q4 2024, Coinbase Global, Inc. (NASDAQ:COIN) added 13 new assets including popular meme coins like PEPE and WIF to its platform. Additionally, the company invested in trading experience improvements and platform stability, and these efforts helped the company’s monthly transacting users (MTUs) grow by nearly 24% to 9.7 million. Coinbase Global, Inc. (NASDAQ:COIN) reported that Q4 2024 total trading volume increased 137% to $439 billion.
In March 2025, Bloomberg reported that Coinbase Global, Inc. (NASDAQ:COIN) is in advanced talks to acquire Deribit, a cryptocurrency derivatives exchange and a leading trading platform for Bitcoin and Ether options. The potential acquisition, which has been communicated to regulators in Dubai, could bolster Coinbase Global, Inc.’s (NASDAQ:COIN) existing derivatives platform. In January, Deribit’s valuation was reported by Bloomberg to be between $4 billion and $5 billion. Deribit holds a license in Dubai which would be transferred to Coinbase Global, Inc. (NASDAQ:COIN) if the deal goes through. However, it remains unclear if a final agreement has been reached.
12. Natera, Inc. (NASDAQ:NTRA)
Year-Over-Year Revenue Growth: 56.75%
Number of Hedge Fund Holders: 77
Natera, Inc. (NASDAQ:NTRA) is a leading cell-free DNA and genetic testing company that primarily focuses on women’s health, cancer, and organ health. The company’s cell-free DNA testing and diagnostics help improve care and inform more personalized decisions. Natera, Inc. (NASDAQ:NTRA) is one of the best aggressive growth stocks to buy now.
Fred Alger Management, an investment management company, stated the following regarding Natera, Inc. (NASDAQ:NTRA) in its “Alger Small Cap Growth Fund” Q4 2024 investor letter:
“Natera, Inc. (NASDAQ:NTRA) is a specialty lab providing genetic testing services in the reproductive health, oncology and transplant markets. Reproductive health tests are run to screen for common genetic disorders such as trisomy 13, 18, and 21 in pregnant women – these tests are also known as non-invasive prenatal testing (NIPT). The company’s oncology franchise is led by Signatera, a test used to detect minimal residual disease (MRD) – the applications of this test are primarily to monitor therapy response and detect cancer recurrence. Lastly, Natera’s transplant franchise is led by Prospera, a test used to monitor transplant organ rejection. Natera’s tests are all based on the company’s proprietary liquid biopsy platform to detect cell-free DNA. During the quarter, shares contributed to performance after the company reported better-than-expected fiscal third quarter revenues, driven by accelerated growth in Signatera, as well as continued market share gains within women’s health business. Moreover, higher pricing and product cost control led to gross margin expansion, as management believes this trend should continue as key productivity initiatives like less costly sequencing in the neo-natal franchise are just beginning to positively impact earnings.”
In Q4 2024, the company saw its total revenue rise 53% year-over-year to $476.1 million. Product revenues also increased by 53.9% and the company’s gross margin improved to 62.9% in Q4 2024 from 51.4% in Q4 2023. Natera, Inc. (NASDAQ:NTRA) reported volumes were up 26% compared to Q4 2023. This was driven by Signatera, which had a standout year with clinical volumes rising about 60% compared to Q4 2023, and nearly 15,000 units of growth over Q3 2024.